US Patent

US8791097 — Anti-tumor activity of CCI-779 in papillary renal cell cancer

Method of Use · Assigned to Wyeth LLC · Expires 2032-05-10 · 6y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of CCI-779 in treating papillary renal cell carcinoma.

USPTO Abstract

This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.

Drugs covered by this patent

Torisel (temsirolimus) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1551`	—	Torisel

Patent Metadata

Patent number: US8791097
Jurisdiction: US
Classification: Method of Use
Expires: 2032-05-10
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.